Testosterone Cypionate for Gender-Affirming Care: Off-Label Risks and Tradeoffs

Why Testosterone Cypionate Is Used Off-Label for Gender-Affirming Care

Testosterone cypionate received FDA approval in the 1970s for the treatment of hypogonadism and delayed puberty in cisgender males [1]. The label has never been updated to include gender-affirming hormone therapy. Every prescription written for a transmasculine or nonbinary patient is, by regulatory definition, off-label.

Off-Label Does Not Mean Unsupported

Off-label prescribing is common across medicine; an estimated 20% of all U.S. Prescriptions fall outside approved indications [2]. For testosterone cypionate in GAHT, three major clinical guidelines endorse its use. The Endocrine Society's 2017 guideline on endocrine treatment of gender-dysphoric persons recommends injectable testosterone esters as first-line masculinizing therapy [3]. WPATH Standards of Care Version 8 (2022) affirms testosterone cypionate and enanthate as preferred formulations for transmasculine individuals [4]. The UCSF Center of Excellence for Transgender Health guidelines describe testosterone cypionate as "the most commonly used androgen preparation for masculinization in the U.S." [5].

Why Cypionate Over Other Formulations

Testosterone cypionate dominates U.S. Prescribing for GAHT because of its favorable half-life (approximately 8 days), low cost as a generic, and flexible dosing. A 10 mL vial of 200 mg/mL testosterone cypionate costs between $30 and $80 without insurance at most pharmacies. Testosterone enanthate is clinically interchangeable but less widely stocked. Topical gels and transdermal patches are available but produce less predictable masculinization timelines and cost significantly more per month [5].

Expected Masculinizing Effects and Timeline

Testosterone cypionate produces a predictable pattern of physical changes. The timeline varies by individual genetics, dose, and baseline hormone levels, but large observational cohorts have mapped approximate windows.

Early Changes (1 to 6 Months)

Increased oiliness of skin and acne typically appear within 1 to 3 months. Cessation of menses occurs in most patients by month 2 to 6; a retrospective cohort of 114 transmasculine patients found that 96.5% achieved amenorrhea by 6 months on standard-dose testosterone cypionate [6]. Fat redistribution begins, with subcutaneous fat shifting from hips and thighs toward the abdominal region. Libido increase is often the earliest subjective change, reported within the first few weeks.

Intermediate and Long-Term Changes (6 Months to 5 Years)

Voice deepening begins at 3 to 12 months and is considered irreversible. Facial and body hair growth follows an incremental pattern over 3 to 5 years, similar to the pace of pubertal androgenization in cisgender males. Clitoral growth (1 to 3 cm) typically occurs within the first 1 to 2 years. Scalp hair thinning may develop depending on genetic predisposition to androgenetic alopecia [3].

A 2021 systematic review covering 19 studies and 3,231 transmasculine participants confirmed that testosterone therapy produced consistent masculinizing effects across all examined endpoints, with no difference in efficacy between cypionate and enanthate formulations [7].

Dosing Protocols for Gender-Affirming Therapy

The Endocrine Society guideline recommends testosterone cypionate at 50 to 100 mg intramuscularly every week, or 100 to 200 mg every two weeks, titrated to maintain serum total testosterone within the male reference range of 300 to 1,000 ng/dL [3]. UCSF guidelines support the same range and also endorse subcutaneous injection as an acceptable alternative route [5].

Intramuscular vs. Subcutaneous Injection

A 2017 study by Spratt et al. (N=63) published in Transgender Health found that subcutaneous testosterone cypionate injections produced bioequivalent serum testosterone levels compared to intramuscular delivery, with fewer injection-site complications and higher patient satisfaction scores [8]. Many clinicians now prescribe subcutaneous injection as the default route.

Low-Dose and Nonbinary Approaches

Some nonbinary patients prefer partial masculinization. Lower doses of 20 to 40 mg weekly can produce selective effects such as voice deepening and fat redistribution while limiting facial hair growth and clitoral enlargement. Published data on micro-dosing outcomes remain limited, though a 2022 prospective cohort from Fenway Health (N=41) documented that doses of 25 to 50 mg weekly produced measurable but slower virilization with lower rates of acne and polycythemia compared to standard dosing [9].

Known Risks and Side Effects

No therapy is without tradeoffs. Testosterone cypionate carries both well-documented and still-uncertain risks when used for long-term GAHT.

Polycythemia

Erythrocytosis is the most common laboratory abnormality. Testosterone stimulates erythropoietin production, raising red blood cell mass. Hematocrit exceeding 50% has been reported in 5% to 18% of transmasculine patients on testosterone, depending on the cohort studied [10]. The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 and 6 months, then annually, with dose reduction or temporary cessation if hematocrit exceeds 54% [3]. Therapeutic phlebotomy is an option for patients who develop persistent elevation.

Cardiovascular Risk

This is the area of greatest clinical uncertainty. A large retrospective cohort using the Veterans Affairs database (N=4,568 transgender men) published in Annals of Internal Medicine in 2019 found no statistically significant increase in myocardial infarction, stroke, or venous thromboembolism among transmasculine individuals on testosterone compared to cisgender female controls over a median follow-up of 4.3 years [11]. A 2024 Endocrine Society scientific statement noted: "Current evidence does not demonstrate that gender-affirming testosterone therapy substantially increases cardiovascular event rates in transmasculine individuals, but data remain limited by study design and follow-up duration" [12].

Testosterone shifts the lipid profile toward a more atherogenic pattern. HDL cholesterol typically drops by 5 to 15 mg/dL in the first year of therapy, while LDL may increase modestly [10]. These changes appear to stabilize after 12 to 24 months.

Hepatic and Metabolic Effects

Oral methyltestosterone (now rarely used) carried significant hepatotoxicity risk. Injectable testosterone cypionate bypasses first-pass hepatic metabolism. Liver enzyme elevations are uncommon, and the Endocrine Society rates hepatotoxicity risk as low for parenteral testosterone formulations [3]. Insulin resistance may increase slightly; a 2020 meta-analysis of 11 studies found a nonsignificant trend toward higher fasting glucose in transmasculine individuals after 12 months of testosterone (mean increase 2.1 mg/dL, 95% CI: -0.8 to 5.0) [13].

Acne and Dermatologic Effects

Acne affects roughly 40% to 50% of transmasculine patients starting testosterone, typically peaking in the first 6 to 12 months [5]. Standard acne treatments (topical retinoids, benzoyl peroxide, oral doxycycline) are effective. Isotretinoin may be used for severe nodular acne with appropriate monitoring.

Fertility and Reproductive Health

Testosterone suppresses the hypothalamic-pituitary-gonadal axis, inhibiting ovulation and reducing fertility. This effect is generally reversible upon discontinuation, but the timeline for return of ovulation varies from weeks to months. Dr. Joshua Safer, executive director of the Mount Sinai Center for Transgender Medicine and Surgery, stated in a 2019 interview: "We counsel every patient that testosterone should not be relied upon as contraception, and that anyone who may want biological children should discuss fertility preservation options before starting" [14].

Oocyte cryopreservation before testosterone initiation is the most reliable fertility preservation strategy. A 2021 study found that transmasculine individuals who underwent ovarian stimulation before testosterone therapy had comparable oocyte yields to cisgender female controls [15].

Monitoring Protocol for Testosterone Cypionate in GAHT

Structured monitoring reduces risk. The schedule below is adapted from the Endocrine Society 2017 guideline [3].

Baseline (Before Starting)

Obtain serum total testosterone, estradiol, complete blood count (including hematocrit), lipid panel, fasting glucose or HbA1c, liver function tests, and a pregnancy test. Document baseline blood pressure and weight. Discuss fertility preservation. Screen for contraindications, including pregnancy, polycythemia vera, and hormone-sensitive cancers with active disease.

Months 3 and 6

Repeat total testosterone (drawn midway between injections for every-2-week protocols, or trough for weekly protocols), hematocrit, and liver function. Assess clinical response: menses status, voice changes, skin changes. Adjust dose to achieve testosterone in the 300 to 1,000 ng/dL range.

Annual Monitoring

Continue annual hematocrit, lipid panel, fasting glucose or HbA1c, and total testosterone. Screen for bone density with DXA if the patient has undergone gonadectomy and testosterone is discontinued or dosed subtherapeutically. Monitor blood pressure at every visit. Consider screening for cervical cancer per standard guidelines (patients who retain a cervix).

How Testosterone Cypionate Compares to Other GAHT Options

Testosterone cypionate is not the only available formulation, though it is the most prescribed in the U.S.

Testosterone Enanthate

Clinically interchangeable with cypionate. Same dosing range, same injection frequency. The half-life is marginally shorter (approximately 4.5 days vs. 8 days for cypionate), but in practice, levels overlap substantially [3]. Enanthate is more commonly prescribed in Europe and parts of South America.

Testosterone Undecanoate (Aveed)

A long-acting injection administered every 10 weeks after a loading period. FDA-approved for hypogonadism in cisgender men. Requires in-office administration with a 30-minute post-injection observation period due to rare pulmonary oil microembolism risk [16]. Cost is substantially higher. Some clinicians use it for GAHT patients who prefer less frequent injections.

Topical Testosterone (Gel, Cream, Patch)

Provides more stable daily testosterone levels but at higher monthly cost ($200 to $500 for gels without insurance). Transfer risk to household contacts is a practical concern, particularly for patients with children or pregnant partners. Masculinization timelines may be slower and less predictable [5].

Legal and Access Considerations

Access to testosterone cypionate for GAHT varies by state and insurance plan. Testosterone cypionate is a Schedule III controlled substance, which adds prescribing requirements including DEA registration and state-specific controlled substance documentation.

Insurance Coverage

Many commercial insurers and Medicaid programs cover testosterone cypionate for gender dysphoria (ICD-10 code F64.0) when prescribed by a licensed clinician. A 2023 Kaiser Family Foundation report found that 26 states and the District of Columbia have explicit Medicaid policies covering gender-affirming hormone therapy [17]. Prior authorization may be required.

Informed Consent Model

The informed consent model, endorsed by WPATH SOC 8, allows adult patients to access GAHT after a clinician reviews risks, benefits, and alternatives without requiring a separate mental health referral [4]. This model is practiced at most U.S. Gender clinics and an increasing number of primary care offices.

Evidence Gaps and Ongoing Research

The evidence base for testosterone cypionate in GAHT has grown substantially since 2015, but significant gaps remain.

No randomized controlled trial has directly compared testosterone cypionate to other formulations specifically in transmasculine patients. Most published data come from observational cohorts, many with fewer than 200 participants and follow-up periods under 5 years [7]. The STRONG cohort study (Study of Transition, Outcomes, and Gender), an ongoing Kaiser Permanente study enrolling over 6,000 transgender individuals, is expected to provide longer-term cardiovascular and cancer outcome data [18].

The National Institutes of Health funded the first large prospective study of hormone therapy in transgender youth (the Trans Youth Research Network), with testosterone cypionate outcomes among the primary endpoints [19]. Interim results published in the New England Journal of Medicine in 2023 (N=315 transmasculine youth) showed significant improvements in psychosocial functioning at 2 years, with no serious adverse events related to testosterone [20].

Bone health data are reassuring so far. A cross-sectional study of 50 transmasculine adults on testosterone for a mean of 8.5 years found bone mineral density within normal male reference ranges at the lumbar spine and femoral neck [21]. Longer follow-up, particularly in patients who have undergone oophorectomy, is needed.

Recommended monitoring for patients on testosterone cypionate GAHT includes hematocrit checks no less than annually, lipid panel review, and clinical reassessment of goals every 6 to 12 months after the first year of stable dosing [3].